Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 9/20 | 0.43 |
| ▸ | CTSL | P07711 | 8/20 | 0.43 |
| ▸ | CTSK | P43235 | 6/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 3/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17710654 | 1.00 | CTSS (0.43) | CTSSCTSLCTSKTSHRCTSB | |
| SCHEMBL28855532 | 0.83 | TSHR (0.42) | CTSSCTSLCTSKTSHRCTSB | |
| SCHEMBL14139311 | 0.81 | TSHR (0.47) | CTSSCTSLCTSKTSHRCTSB | |
| SCHEMBL30868576 | 0.81 | TSHR (0.47) | CTSSCTSLCTSKTSHRCTSB | |
| SCHEMBL14763820 | 0.78 | TSHR (0.56) | TSHRCTSBNAAACA1CA2 | |
| SCHEMBL155702 | 0.78 | TSHR (0.56) | TSHRCTSBNAAACA1CA2 | |
| SCHEMBL17710649 | 0.76 | CA1 (0.47) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL17710648 | 0.76 | CA1 (0.47) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL10657232 | 0.74 | TSHR (0.47) | CTSLCTSKTSHRCTSBNAAA | |
| SCHEMBL31567153 | 0.74 | TSHR (0.42) | CTSSCTSLCTSKTSHRCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422230-B2 | Process for the preparation of an anticonvulsant agent pregabalin hydrochloride | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-08-23 | — | — | US | disclosed |
| US-20160122289-A1 | PROCESS FOR THE PREPARATION OF AN ANTICONVULSANT AGENT PREGABALIN HYDROCHLORIDE | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122289-A1 | PROCESS FOR THE PREPARATION OF AN ANTICONVULSANT AGENT PREGABALIN HYDROCHLORIDE | GABRE, GABRG1, GABRB2 | CTSS 3764/4885CTSL 3484/4885CTSK 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.